Answers are grounded in this paper and cite their sources.
Investigates antibacterial effects of synthesized compounds in bacterial strains, indicating potential as drug candidates.
In the present investigation, two compounds, 4-methyl-N-(4-nitrobenzylidene) aniline (3) and 4-methyl-N-(4-nitrobenzyl)aniline (4), were successfully synthesized through an efficient synthetic method and obtained in good yields. Synthesized Schiff base was further reduced via NaBH4, and their structures were confirmed by[1] H NMR spectra. Synthesized compounds displayed broad-spectrum antibacterial activity against Staphylococcus aureus, Bacillus subtilis, Escherichia coli, and Klebsiella pneumoniae with moderate to good inhibitory effects. Compound 3 showed good antibacterial potency against S. aureus (24 mm) and K. pneumoniae (20 mm). Further, molecular docking studies against the target protein (PDB ID: 1KZN, E. coli) exhibited good binding affinity (docking scores of -7.7 and -7.4 kcal/mol) with diverse binding interactions with active-site residues. ADME prediction revealed satisfactory pharmacokinetic profiles for both compounds, including high gastrointestinal absorption, BBB permeability, and non-substrate behavior toward P-glycoprotein. Further, zero Lipinski rule violations and a bioavailability score of 0.55, suggesting good oral drug-likeness. Overall, both compounds exhibited promising antibacterial activity, favorable binding interactions, pharmacokinetic and toxicity properties, thus representing promising scaffolds for further study and biological evaluation.
No takes yet. Share an insight, caveat, or question.
Shailesh S. Gurav1*, Seema R. Jadhav2, Pranaya P. Iswalkar3 (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: